| Primary information |
|---|
| ThPP ID | Th1092 |
| Therapeutic Peptide/Protein Name | Arcitumomab |
| Sequence | Anti-CEA heavy chain 1EVKLVESGGGLVQPGGSLRLSCATSGFT view full sequnce in fasta |
| Functional Classification | IIb |
| Molecular Weight | 144482.5 |
| Chemical Formula | C6398H9900N1714O1995S54 |
| Isoelectric Point | 8.26 |
| Hydrophobicity | -0.423 |
| Melting Point (℃) | 61 (FAB fr |
| Half Life | Approximately 1 hour |
| Description | Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen. Covalently labeled with Technitium 99. |
| Indication/Disease | For imaging colorectal tumors |
| Pharmacodynamics | Binds to the carcinoembryonic antigen, which is a cell surface protein generally overexpressed in colon (and other) cancers. The radioactive Tc99, which is covalently attached to the antibody, allows radiodiagnostic detection of CEA expressing cells and tumors |
| Mechanism of Action | Binds selectively to cell-surface carcinoembryonic antigen (CEA) expressed on colorectal tumors. |
| Toxicity | N.A. |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system, or by human antimurine antibody production |
| Absorption | N.A. |
| Volume of Distribution | N.A. |
| Clearance | N.A. |
| Categories | Diagnostic Agents |
| Patents Number | US8420081 |
| Date of Issue | N.A. |
| Date of Expiry | N.A. |
| Drug Interaction | N.A. |
| Target | Vascular endothelial growth factor A,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
| Information of corresponding available drug in the market |
|---|
| Brand Name | CEA-Scan |
| Company | N.A. |
| Brand Discription | Arcitumomab, a Fab fragment of the murine monoclonal antibody IMMU-4 of the IgG1 subclass, is directed against a 200,000-dalton carcinoembryonic antigen (CEA) that is expressed on the cell surface of numerous tumors, particularly of the gastrointestinal tract (including fetal gastrointestinal tissues) and in certain inflammatory states (e.g., Crohns disease). The Fab fragment is used rather than the whole monoclonal antibody because of its more favorable pharmacokinetics (faster blood clearance and minimal liver metabolism) also, it minimizes the frequency of human anti-mouse antibody response. Less than 50% antigen complexation with technetium Tc 99m arcitumomab occurs with plasma CEA levels of up to 2000 nanograms per mL, and antigen complexation is not detectable at serum CEA levels below 250 nanograms per mL. The distribution of radioactivity is recorded by planar scintigraphy and single photon emission computed tomography (SPECT) |
| Prescribed for | Diagnostic: Carcinoma, colorectal (diagnosis adjunct)—Technetium Tc 99m arcitumomab, in conjunction with standard diagnostic modalities (e.g., computed tomography [CT]), is indicated to detect, locate, and determine the extent of recurrent and/or metastatic colorectal carcinoma involving the liver and the extrahepatic abdominal and pelvic regions in patients with a histologically confirmed diagnosis of colorectal carcinoma. maging with technetium Tc 99m arcitumomab provides additional information in patients suspected of tumor recurrence or metastasis who have elevated or rising serum carcinoembryonic antigen (CEA) but no evidence of disease by standard diagnostic methods (e.g., abdominal and pelvic CT, chest radiograph, colonoscopy, barium enema). |
| Chemical Name | N. A. |
| Formulation | N. A. |
| Physcial Appearnce | N. A. |
| Route of Administration | N. A. |
| Recommended Dosage | N. A. |
| Contraindication | You should not receive this medicine if you have had an allergic reaction to arcitumomab, or to products made from mice. Technetium Tc 99m arcitumomab may have a role as an adjunct to mammography in the diagnosis of primary, recurrent, or metastatic mammary cancer, particularly in patients without palpable abnormalities who have indeterminate mammograms. |
| Side Effects | Allergic reaction: Itching or hives, swelling in your face or hands, swelling or tingling in your mouth or throat, chest tightness, trouble breathing, Chest tightness or severe cough, Headache, Joint pain, Mild skin rash or itching, Nausea or upset stomach. |
| Useful Link | http://umm.edu/health/medical/drug-notes/notes/arcitumomab-injection http://www.drugs.com/mmx/cea-scan.html |
| PubMed ID | 20641871, 11776491, 10855627, 10656657 |
| 3-D Structure | Th1092 (View) or (Download) |